The Critical Path Institute said on Tuesday that it received a three-year grant from the Bill & Melinda Gates Foundation that will be used to optimize the design of clinical trials and overcome challenges in developing tuberculosis treatments.
The work will be focused on TB drug treatments, and will be implemented through the Critical Path to TB Drug Regimens Initiative. The initiative was co-founded by the institute, the Gates foundation and the Global Alliance for TB Drug Development.
"TB is a pressing global public health issue and stopping its spread requires new treatment options," Martha Brumfield, the president and chief executive officer of the Critical Path Institute, said. "This grant and the collaborative work of CPTR will reduce the time and uncertainty in developing innovative regimens from decades to years."
The grant allows the institute to test drug combinations and create new multi-drug treatments.
In support of the project, Janssen Research & Development will provide information from its clinical trials of Sirturo, a new TB treatment.
"We are proud to actively contribute to CPTR and foster new ways to tackle the challenge of TB," Wim Parys, the head of research and development at Global Public Health at Janssen Pharmaceuticals, said. "Through our collaborations with the CPTR Initiative we look forward to continuing to provide safe, efficacious and faster-acting TB regimens for individuals impacted by this terrible disease."